Knights of Columbus Asset Advisors LLC Has $6.87 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Knights of Columbus Asset Advisors LLC lifted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 99.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 185,845 shares of the biopharmaceutical company’s stock after acquiring an additional 92,552 shares during the quarter. Knights of Columbus Asset Advisors LLC’s holdings in Halozyme Therapeutics were worth $6,869,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Harvey Capital Management Inc. acquired a new position in Halozyme Therapeutics during the 4th quarter worth $5,918,000. Hsbc Holdings PLC raised its position in shares of Halozyme Therapeutics by 35.0% during the 3rd quarter. Hsbc Holdings PLC now owns 78,404 shares of the biopharmaceutical company’s stock valued at $3,006,000 after acquiring an additional 20,346 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Halozyme Therapeutics by 174.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company’s stock valued at $33,894,000 after acquiring an additional 563,989 shares during the last quarter. Aurora Investment Counsel bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at $1,347,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at $591,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $39.55, for a total value of $395,500.00. Following the completion of the sale, the senior vice president now directly owns 156,558 shares in the company, valued at approximately $6,191,868.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders sold 30,000 shares of company stock worth $1,196,800. Insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on HALO shares. Benchmark restated a “buy” rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a research report on Tuesday. StockNews.com upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, February 23rd. JMP Securities restated a “market outperform” rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, February 21st. TD Cowen started coverage on shares of Halozyme Therapeutics in a research note on Thursday, February 29th. They issued an “outperform” rating and a $54.00 target price for the company. Finally, The Goldman Sachs Group reduced their target price on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday, January 18th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $53.29.

Halozyme Therapeutics Stock Up 0.9 %

Shares of Halozyme Therapeutics stock traded up $0.33 during trading hours on Friday, reaching $38.14. 291,710 shares of the company’s stock were exchanged, compared to its average volume of 1,258,643. The company has a 50 day moving average of $39.50 and a two-hundred day moving average of $37.76. Halozyme Therapeutics, Inc. has a fifty-two week low of $29.85 and a fifty-two week high of $45.00. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89. The stock has a market cap of $4.85 billion, a P/E ratio of 17.92, a P/E/G ratio of 0.44 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. The business had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. On average, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 3.45 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.